Opportunities and challenges in vaccine delivery

European Journal of Pharmaceutical Sciences

Volumn 36, Issue 4-5, 2009, Pages 605-608

  Carstens, Myrra G ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

Author keywords

Adjuvant technology; Antigen formulation; EUFEPS workshop report; Needle free delivery; Particulate delivery systems; Vaccine delivery

Indexed keywords

ADJUVANT; DNA VACCINE; INFLUENZA VACCINE; MICROSPHERE; NASAFLU; OCTOVAX; UNCLASSIFIED DRUG; VACCINE;

ARTICLE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; DRUG STABILITY; GENE GUN; IMMUNOGENICITY; NEEDLE; PARTICULATE DELIVERY SYSTEM; PRIORITY JOURNAL;

EID: 59349085503     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2008.11.004     Document Type: Note

References (34)

1. Agger E.M., Rosenkrands I., Hansen J., Brahimi K., Vandahl B.S., Aagaard C., Werninghaus K., Kirschning C., Lang R., Christensen D., Theisen M., Follmann F., and Andersen P. Cationic liposomes formulated with synthetic mycobacterial cordfactor (CAF01): a versatile adjuvant for vaccines with different immunological requirements. PLoS ONE 3 (2008) e3116
2. Amidi M., Romeijn S.G., Verhoef J.C., Junginger H.E., Bungener L., Huckriede A., Crommelin D.J., and Jiskoot W. N-Trimethyl chitosan (TMC) nanoparticles loaded with influenza subunit antigen for intranasal vaccination: biological properties and immunogenicity in a mouse model. Vaccine 25 (2007) 144-153
3. Ansaldi F., Bacilieri S., Durando P., Sticchi L., Valle L., Montomoli E., Icardi G., Gasparini R., and Crovari P. Cross-protection by MF59-adjuvanted influenza vaccine: neutralizing and haemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses. Vaccine 26 (2008) 1525-1529
4. Bachmann M.F., and Dyer M.R. Therapeutic vaccination for chronic diseases: a new class of drugs in sight. Nat. Rev. Drug Discov. 3 (2004) 81-88
5. Bal S.M., Caussin J., Pavel S., and Bouwstra J.A. In vivo assessment of safety of microneedle arrays in human skin. Eur. J. Pharm. Sci. 35 (2008) 193-202
6. Bivas-Benita M., Ottenhoff T.H., Junginger H.E., and Borchard G. Pulmonary DNA vaccination: concepts, possibilities and perspectives. J. Control. Release 107 (2005) 1-29
7. Bivas-Benita M., van Meijgaarden K.E., Franken K.L., Junginger H.E., Borchard G., Ottenhoff T.H., and Geluk A. Pulmonary delivery of chitosan-DNA nanoparticles enhances the immunogenicity of a DNA vaccine encoding HLA-A*0201-restricted T-cell epitopes of Mycobacterium tuberculosis. Vaccine 22 (2004) 1609-1615
8. Friede M., and Aguado M.T. Need for new vaccine formulations and potential of particulate antigen and DNA delivery systems. Adv. Drug Deliv. Rev. 57 (2005) 325-331
9. Glueck R. Pre-clinical and clinical investigation of the safety of a novel adjuvant for intranasal immunization. Vaccine 20 Suppl. 1 (2001) S42-S44
10. Honeywell-Nguyen P.L., Groenink H.W.M., and Bouwstra J.A. Elastic vesicles as a tool for dermal and transdermal delivery. J. Liposome Res. 16 (2006) 273-280
11. Johansen P., Martinez Gomez J.M., and Gander B. Development of synthetic biodegradable microparticulate vaccines: a roller coaster story. Expert Rev. Vacc. 6 (2007) 471-474
12. Kendall M. Engineering of needle-free physical methods to target epidermal cells for DNA vaccination. Vaccine 24 (2006) 4651-4656
13. Kendall M., Mitchell T., and Wrighton-Smith P. Intradermal ballistic delivery of micro-particles into excised human skin for pharmaceutical applications. J. Biomech. 37 (2004) 1733-1741
14. Kersten G.F., and Crommelin D.J. Liposomes and ISCOMs. Vaccine 21 (2003) 915-920
15. Lavelle E.C. Lectins and microparticles for enhanced oral vaccination. Methods 38 (2006) 84-89
16. Lavelle E.C., Grant G., Pfuller U., and O'Hagan D.T. Immunological implications of the use of plant lectins for drug and vaccine targeting to the gastrointestinal tract. J. Drug Target. 12 (2004) 89-95
17. MacDonald K.P., Munster D.J., Clark G.J., Dzionek A., Schmitz J., and Hart D.N. Characterization of human blood dendritic cell subsets. Blood 100 (2002) 4512-4520
18. Martinez Gomez J.M., Fischer S., Csaba N., Kündig T.M., Merkle H.P., Gander B., and Johansen P. A protective allergy vaccine based on CpG- and protamine-containing PLGA microparticles. Pharm. Res. 24 (2007) 1927-1935
19. McBurney W.T., Lendemans D.G., Myschik J., Hennessy T., Rades T., and Hook S. In vivo activity of cationic immune stimulating complexes (PLUSCOMs). Vaccine 26 (2008) 4549-4556
20. Myschik J., McBurney W.T., Rades T., and Hook S. Immunostimulatory lipid implants containing Quil-A and DC-cholesterol. Int. J. Pharm. 363 (2008) 91-98
21. O'Hagan D.T. MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection. Expert Rev. Vacc. 6 (2007) 699-710
22. O'Hagan D.T., Wack A., and Podda A. MF59 is a safe and potent vaccine adjuvant for flu vaccines in humans: what did we learn during its development?. Clin. Pharmacol. Ther. 82 (2007) 740-744
23. Perrie Y., Frederik P.M., and Gregoriadis G. Liposome-mediated DNA vaccination: the effect of vesicle composition. Vaccine 19 (2001) 3301-3310
24. Perrie Y., McNeil S., and Vangala A. Liposome-mediated DNA immunisation via the subcutaneous route. J. Drug Target. 11 (2003) 555-563
25. Rappuoli R., and Covacci A. Reverse vaccinology and genomics. Science 302 (2003) 602
26. Saupe A., McBurney W., Rades T., and Hook S. Immunostimulatory colloidal delivery systems for cancer vaccines. Expert Opin. Drug Deliv. 3 (2006) 345-354
27. Schijns V.E. Mechanisms of vaccine adjuvant activity: initiation and regulation of immune responses by vaccine adjuvants. Vaccine 21 (2003) 829-831
28. Schijns V.E., and Degen W.G. Vaccine immunopotentiators of the future. Clin. Pharmacol. Ther. 82 (2007) 750-755
29. Serruto D., and Rappuoli R. Post-genomic vaccine development. FEBS Lett. 580 (2006) 2985-2992
30. Siegrist C.A. Neonatal and early life vaccinology. Vaccine 19 (2001) 3331-3346
31. Slutter B., Hagenaars N., and Jiskoot W. Rational design of nasal vaccines. J. Drug Target. 16 (2008) 1-17
32. Spohn G., and Bachmann M.F. Exploiting viral properties for the rational design of modern vaccines. Expert Rev. Vacc. 7 (2008) 43-54
33. Verbaan F.J., Bal S.M., van den Berg D.J., Groenink W.H., Verpoorten H., Luttge R., and Bouwstra J.A. Assembled microneedle arrays enhance the transport of compounds varying over a large range of molecular weight across human dermatomed skin. J. Control. Release 117 (2007) 238-245
34. Vulink A., Radford K.J., Melief C., and Hart D.N. Dendritic cells in cancer immunotherapy. Adv. Cancer Res. 99 (2008) 363-407